Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of generic pioglitazone 30 mg versus Actos in healthy Thai volunteers under fasting conditions
TCTR20260804007Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pioglitazone (2 arms), sponsored by International Bio Service. Primary endpoints: Maximum plasma concentration (Cmax), AUC0-tlast and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
pioglitazone
Beyond the preview
Go deeper on TCTR20260804007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260804007.